US FDA’s ADHD Drug Relabeling Advances A MAHA Priority, Reviving Data Dispute

 
• By Bridget Silverman
  
The US FDA wants to protect young children from the risk of growth suppression posed by extended-release stimulants for ADHD. (Shutterstock)

More from Drug Safety

More from Pink Sheet